Flow Cytometric Analysis of Benign and Malignant Tumors

良性和恶性肿瘤的流式细胞术分析

• 批准号: 9154363
• 负责人: Maryalice Stetler-Stevenson
• 金额: $ 160.33万
• 依托单位: DIVISION OF CLINICAL SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9154363
• 关键词: Antibodies; Benign; Biological Assay; Biopsy; Blood; Body Fluids; Bone Marrow; Cell Surface Proteins; Characteristics; Clinical; Clinical Protocols; Communities; Detection; Detection of Minimal Residual Disease; Diagnosis; Diagnostic tests; Disease; Education; Eligibility Determination; Enrollment; Evaluation; Event; Fine needle aspiration biopsy; Flow Cytometry; Goals; Immunophenotyping; Institution; Laboratories; Malignant - descriptor; Malignant Neoplasms; Measurement; Medical; Medical Staff; Monitor; Neoplasms; Patients; Protocols documentation; Residual state; System; Techniques; Testing; Tissues; United States National Institutes of Health; base; cancer cell; improved; leukemia/lymphoma; medical specialties; neoplastic cell; protein profiling; response; therapeutic evaluation

The Flow Cytometry Unit provides extensive support for NCI clinical protocols by providing diagnostic testing for leukemia and lymphoma in patients either on NCI clinical protocols or undergoing testing to determine eligibility for said protocols. The Flow Cytometry Unit provides clinical flow cytometric evaluation of blood, bone marrow, fine needle aspirates, tissue biopsies and body fluids for hematolymphoid neoplasia in NCI and NIH patients. The majority of flow cytometric testing performed by the Flow Cytometry Unit involves detection of minimal residual disease (patients are status post therapy at outside institution prior to enrollment on NCI protocol) and measurement of specific tumor cell characteristics mandated by various clinical protocols. Significant effort in the unit is devoted to delivery of numerous unique protocol mandated assays that are not offered by commercial laboratories. The Flow Cytometry Unit is also actively engaged in education of the NIH staff and medical community at large in the proper utility of flow cytometry in medical practice.

流式细胞术单位为NCI临床方案提供广泛的支持，为符合NCI临床方案的患者提供白血病和淋巴瘤的诊断测试，或接受测试以确定是否符合所述方案。流式细胞仪单元提供对NCI和NIH患者的血液、骨髓、细针抽吸物、组织活检和体液的临床流式细胞仪评估。流式细胞术单元进行的大多数流式细胞仪测试涉及检测微小残留病(患者在加入NCI方案之前是在外部机构接受治疗后的状态)和各种临床方案要求的特定肿瘤细胞特征的测量。该单位的大量工作致力于交付商业实验室不提供的许多独特的协议规定的分析。流式细胞术股还积极参与对国家卫生研究院工作人员和广大医学界的教育，使其了解流式细胞术在医疗实践中的适当用途。